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Summary Background Hepatocellular carcinoma (HCC)
cells are auxotrophic for arginine, depletion of which leads
to tumour regression. The current study evaluated safety,
pharmacokinetics (PK)/ pharmacodynamics (PD) parameters,
and potential anti-tumor activity of pegylated recombinant
human arginase 1 (peg-rhArg1) in advanced HCC patients.
Methods Eligibility criteria included advanced HCC with
measurable lesions, Child-Pugh A or B, and adequate organ
function. Initial single IV bolus was followed by weekly doses
of peg-rhArgI escalated from 500 U/kg to 2500 U/kg in a 3+3
design. Results Fifteen patients were enrolled at weekly doses
of 500 U/kg (n03), 1000 U/kg (n03), 1600 U/kg (n03) and
2500U/kg (n06). The median age was 57 years (33–74); 87%
were hepatitis B carriers and 47% had prior systemic treat-
ment. The most commonly reported drug-related non-
haematological adverse events (AEs) were diarrhea (13.3%),
abdominal discomfort (6.7%) and nausea (6.7%). No drug-
related haematological AEs were seen. Only 1 of the six
patients that received 2500U/kg peg-rhArg1 experienced
DLT (grade 4 bilirubin elevation) and thus the maximum
tolerated dose was 2500 U/kg. PK and PD analysis
indicated that peg-rhArg1 was efficacious in inducing
arginine depletion in a dose-dependent manner. Adequate
arginine depletion dose was achieved in the 1,600–
2,500 U/kg range and therefore the optimal biological
dose was at 1600 U/kg, which was chosen as the rec-
ommended dose. The best response was stable disease
for >8 weeks in 26.7% of the enrolled patients. Conclusion
Peg-rhArg1 has manageable safety profile and preliminary
evidence of activity in advanced HCC patients.
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Background
Hepatocellular carcinoma (HCC) is the third most common
cause of cancer-related death [1]. While long-term survival
of patients with early HCC amenable to surgical treatment
has improved in recent years, prognosis of patients with
advanced disease remains poor with the median overall
survival (OS) usually around 3 months from the time of
diagnosis of the advanced disease [2].
HCC is relatively chemo-resistant. Thus far, there are no
convincing phase III data to suggest that systemic chemo-
therapy, whether singly or in combination, improves overall
survival in patients with advanced disease [3]. Notably, the
use of the new generation of chemotherapy, such as oxali-
platin has recently demonstrated seemingly encouraging
results. In particular, the results of the randomised phase 3
trial in comparing the efficacy of oxaliplatin plus 5-
Flurourcail and Leucovorin versus doxorubicin (FOLFOX4)
as the palliative treatment for advanced HCC was reported
in the ASCO meeting 2010 by Quinn et al [4]. The prelim-
inary results showed that FOLFOX resulted in better overall
survival and better tolerability than patients received doxo-
rubicin. Thus, the future role of oxaliplatin in the treatment
algorithm of advanced HCC patients is being investigated in
the ongoing trials in advanced HCC population. Recently,
two pivotal phase-III randomized placebo-controlled trials
in the West [5] and Asia-Pacific region [6] have shown
benefit with single agent sorafenib in patients with advanced
HCC. Based on these studies, sorafenib was approved for
the management of advanced HCC patients. It is noteworthy
that the OS of patients on sorafenib was only 6.5 months,
compared with 4.2 months in patients on placebo [6]. Thus,
the overall improvement in OS is around 2.3 months. Fur-
thermore, the treatment side effects from sorafenib, such as
hand-foot-skin reaction and fatigue should not be lightly
dismissed. Therefore, an unmet medical need remains to
develop more effective therapeutic agents with significantly
less side effects in the treatment of advanced HCC.
Arginine is a semi-essential amino acid involved in the
synthesis of a wide range of peptides, proteins, and a myriad
of metabolic pathways and cellular events [7]. HCC cells are
said to be auxotrophic for arginine since they cannot, like
normal somatic cells, recycle arginine from citrulline, mak-
ing them completely reliant on exogenous arginine for
growth. Thus, there are potential benefits in using arginine
deprivation therapy in treating HCC. In vitro, arginine de-
pletion strongly induced tumour regression in argininosuc-
cinate synthase (ASS) deficient HCC cell lines [8]. In vivo,
xenograft studies confirmed that arginine depletion inhibited
tumour growth in murine HCC, which do not express ASS
mRNA. However, when it was transfected with an expres-
sion plasmid containing ASS cDNA, the transfected cells
were much more resistant to arginine depletion [8, 9].
Two major enzyme therapeutics, pegylated arginine dei-
minase and pegylated human hepatic arginase, are now in
various stages of clinical development. Arginine deiminase
(ADI) is a Mycoplasma secreted enzyme that degrades ar-
ginine to citrulline in vivo, releasing ammonia as the other
reaction product [10]. It may control growth of ASS defi-
cient or arginine auxotrophic HCC. The pegylated form of
ADI is now in phase-II clinical trial in HCC and melanoma
and is reported to have moderate disease-stabilizing activity
in HCC [11]. Arginase is another arginine-degrading en-
zyme for use in the treatment of arginine auxotrophic
tumours. Unlike ADI, this non-xenogenic and native (hu-
man) enzyme hydrolyses arginine to ornithine and urea; the
latter is non-toxic and excreted in the urine. The arginase
used in this trial was of Good Manufacturing Practice
(GMP) grade– pegylated recombinant human arginase1
(peg-rhArg1), from an E. coli expression system. After
suitable pegylation to increase its in vivo half-life in plasma
from a few hours to 3–4 days, it has been shown to have
strong in vitro and in vivo anti-tumour activities in a number
of tumour types including HCC [9]. Production of this
pegylated recombinant human arginase 1 has been reported
elsewhere [12].
The aim of this open-label, phase I dose-escalation study
was to evaluate safety, pharmacokinetics (PK)/pharmacody-
namics (PD), and potential anti-tumor activity of peg-
rhArg1 in patients with advanced HCC.
Patients and methods
This was a single-center, prospective, open-label, phase 1
dose-escalation study of peg-rhArg1 in subjects with ad-
vanced HCC unsuitable for either surgical or loco-regional
therapy. The protocol was approved by the local IRB and
Ethics Committee with written consents being obtained
from the patients before enrollment. The trial was registered
in clinicaltrials.gov identifier NCT01092091 and conducted
in compliance with ICH guidance of Good Clinical Practice.
Patient’s eligibility
Advanced HCC patients not suitable for surgery or various
loco-regional therapies at the Queen Mary Hospital, Hong
Kong, were recruited. HCC was diagnosed either by cyto-
histological confirmation or by non-invasive criteria accord-
ing to the European Association for Study of Liver disease
(EASL) criteria: cirrhotic patients with either two coincident
imaging techniques demonstrating focal lesion >2 cm with
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arterial hypervascularization or one imaging technique
showing focal lesion >2 cm with arterial hyper-
vascularization and associated with alpha fetal protein
(AFP) level >400 ng/ml [13]. Staging was by American
Joint Committee on Cancer (AJCC) and Barcelona Clinic
Liver Cancer (BCLC) score. The eligibility criteria included
adult patients 18–75 years old; patients with Child-Pugh
class A or B cirrhosis; Karnofsky performance status
(KPS)≥80%; expected life expectancy of ≥12 weeks and
with adequate organ function: complete blood picture (ab-
solute neutrophil count (ANC) >1.0×109/L, platelet count
>100×109/L) and biochemistry (total bilirubin of ≤2×upper
limit of normal, serum AST and ALT≤5×upper limit of
normal). The disease must be measurable with at least one
lesion, which was at least 2 cm in one dimension either on
CT or MRI scan. All the enrolled patients had clear progres-
sive disease with their last treatment modalities prior to
study entry.
Dosing scheme, dose limiting toxicity and maximum
tolerated dose
Patient enrollment was based on the 3+3 paradigm with dose-
escalating cohorts as shown in Table 1. The escalation scheme
followed the modified Fibonacci scheme commonly used in
phase I trials [14]. DLTwas defined as any grade 4 toxicities,
grade 3 neutropenia or the occurrence of neutropenic sepsis,
grade 3 thrombocytopenia or any grade 3 toxicities that did
not return to grade1/2 within 3 weeks, except for alopecia. The
maximum tolerated dose (MTD) was defined as the highest
weekly level of IV bolus peg-rhArg1 at which no more than
one of six patients experienced a DLT.
Initially, a cohort of 3 advanced HCC patients received a
bolus I.V. administration of peg-rhAgr1 started at 500 U/kg.
Single dose safety parameters, including hematology and
chemistry laboratory profiles, were monitored weekly for
2 weeks. Patients did not demonstrate a dose limiting tox-
icity ( DLT) following the single dose subsequently received
weekly IV bolus of peg-rhArg1 at the same dose level from
week 3 (day 15) onwards (Fig. 1).
Pharmacokinetics(PK) and Pharmacodynamics (PD)
measurement
Plasma arginase and corresponding arginine levels were
measured following bolus I.V. administration of peg-
rhArg1 in groups of 3 patients given a range of peg-
rhArgI. After the dose for each patient, blood samples for
plasma arginase were drawn at baseline, 2 and 4 h after the
single dosing to establish maximum plasma concentration
(Cmax) and initial clearance. Additional single time-point
samples were drawn on Days 2, 4, 6 and 8 to establish the
terminal T1/2 and duration of arginine depletion after the
first dose. During weekly dosing, baseline (pre-dose) sam-
ples and 24 h post dose samples were obtained from weeks 3
to 5; then only one baseline sample from weeks 6 to 11. PK
parameters to be calculated based on a non-compartmental
model approach include: Cmax, time to maximum observed
concentration (Tmax,), minimum observed concentration
(Cmin), and area under the curve (AUC∞). Arginase levels
were assessed using ELISA Kit (BEIJING 4A BIOTECH
Co. LTD, in China). The methodology of these tests is per
standard ELISA protocol. Arginine level was analyzed by a
high-speed amino acid analyzer [15]. Adequate Arginine
Depletion (ADD) dose was defined as the dose of peg-
rhAgr1 that depletes arginine level to <8 μM throughout
Table 1 Patient cohorts
and dosing scheme Cohort U/kg
One 500
Two 1000
Three 1600
Four 2500
Fig. 1 Dose escalating scheme
of Peg-rhArg1
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the treatment period. Optimal Biological Dose (OBD),
which was defined as the lowest dose of peg-rhArg1 to
achieve sustained ADD.
Objectives
The primary objectives of this study were the safety, toler-
ability and in establishing the safety dose of peg-rhArg1 in
the future clinical trials of advanced HCC patients. Second-
ary objectives included characterization of PK/PD and eval-
uation of treatment efficacy per RECIST 1.0 guideline [16].
Disease evaluation
A full history and complete physical examination, including
performance status were performed at every clinical visit.
Disease assessment was performed by CT scan at baseline,
week 11 and week 21. Response was independently
reviewed by a designated radiologist at the Hong Kong
Sanatorium and Hospital throughout the study and classified
according to RECIST 1.0 criteria [16]. Patients who com-
pleted more than 8 weeks of the study were considered as
evaluable for response. Weekly peg-rhArg1 administration
continued (without dose escalation) for patients whose dis-
ease assessments showed either stable disease (SD) or
response.
Safety monitoring
Safety assessments consisted of monitoring and recording
all the adverse and serious adverse events (AEs). Apart from
monitoring of vital signs, regular collection of urine, hema-
tology and blood chemistry of the enrolled subjects were
performed. Patients who received at least one weekly dose
of peg-rhArg1 were defined as Intent-to-treat population and
considered evaluable for safety. AEs were evaluated accord-
ing to National Cancer Institute Criteria (NCIC) version 3.0
[17].
Statistical analysis
Survival analysis was computed by the Kaplan-Meier meth-
od. Progression-free survival (PFS) was calculated from the
date of commencement of study drugs to the date of docu-
mented progression or death. OS was calculated from the
date of commencement of study drugs to the date of death or
last follow-up. The analysis was performed on intent-to-treat
basis. All statistical analysis was performed by Statistical
Package for Social Science version 13.0 for Windows
(SPSS Inc., Chicago, IL USA).
Results
Demographics
Between May 2008 and July 2009, 15 patients were
recruited in the study at weekly doses of 500 U/kg
(3 patients), 1000 U/kg (3 patients), 1600 U/kg (3 patients)
and 2500 U/kg (6 patients). Table 2 shows the demographics
of all the recruited subjects. The median age was 57 years,
and 12 patients (80%) were male. All except 2 were hepa-
titis B carriers; 2 received antiviral treatment for hepatitis B
during peg-rhAgr1 treatment. Eleven (73.3%) patients were
in Child-Pugh A cirrhosis, while the remaining four (26.7%)
were in Child-Pugh B cirrhosis. All the recruited patients
had advanced HCC that belonged to BCLC stage C (100%).
Table 3 shows the details of the prior treatments in the
enrolled patients. Ten (67%) patients had received prior
treatments for HCC, while the remaining 5 patients were
treatment naïve. Notably, seven (47%) patients were heavily
pretreated with various chemotherapy regimens and anti-
VEGF therapies.
Safety and tolerability
The median treatment exposure was 10 weeks (range,
2–23 weeks). Half of the patients had 6 to 12 weeks
treatment exposure. Seven patients did not complete the
8 weeks of study drug. One out of three patients expe-
rienced possible DLT, in cohort 4 (2500 U/kg) with
grade 4 bilirubin elevation in the first month of treat-
ment. An additional 3 patients were recruited into this
cohort as per protocol requirement. No further DLT was
reported in these additional 3 patients. Therefore, the
MTD was defined as 2500 U/kg.
In total, 9 possible drug-related AEs were recorded
(Table 4). Most peg-rhArg1-related toxicities were grade 1
or 2, which resolved after discontinuation of peg-rhArg1.
No treatment-related deaths were reported.
Pharmacokinetics
Figure 2a shows the pharmacokinetics of peg-rhArg1 in
cohort 1-3. Following the first dose of peg-rhArg1, the
mean Cmax at 500, 1000, 1600U/kg were 78.8 (86.5%),
212.0 (35.2%), and 171.3 (17.3%) μg/ml, respectively.
The mean peak-through ratios were 4.23 in cohort 2,
and ranged from 2 to 3 for other 2 cohorts. The mean
AUC∞ was about 8.94 (28.2%) mg*h/ml for cohort 1
(500U/kg). Cohort 2 (1000U/kg) and 3 (1600U/kg) had
similar mean AUC∞, which were 34.67 (58.4%) and
33.36 (20.5%) mg*h/ml respectively.
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Pharmacodynamics
Peg-rhArg1 was efficacious in inducing arginine depletion in
a dose-dependent manner. Figure 2b shows the relationship
between plasma arginine levels after peg-rhArg1 dosing. The
time taken to achieve undetectable plasma of arginine was 2 h
for all patients following a single dose. The 2500U/kg dose
level in cohort 4 had the greatest arginine depletion and the
highest median duration of the ADD effect (166 h). In cohort 3
(1600U/kg), the effective ADD was achieved after the second
weekly dose of peg-rhArg1 and ADD was maintained
throughout the treatment period. The lowest dose of peg-
rhAgr1 that achieved ADD was 1600U/kg in cohort 3 and
this dose was therefore deemed the OBD.
Recommended safe dose of Peg-rhArg1
The study was terminated on completion of all the 6 cases in
cohort 4 since both the MTD (2500 U/kg) and OBD
(1600U/kg) were established. The final recommended safe
dose for future clinical trials was chosen as 1600U/kg in-
stead of 2500 U/kg based on the premise that it was the
Table 3 Summary of prior treatments in enrolled subjects
Subject Number Prior Treatment Summary
101 Right Hepatectomy
102 TACE (Cisplatin) : 3X
201 Liver Resection;
Radiofrequency Ablation;
Doxorubicin: 6 cycles;
TACE (Cisplatin): 2X;
Anti-VEGF: 6 cycles
202 Right Hepatectomy;
Doxorubicin: 6 cycles;
Anti-VEGF: 6 cycles
203 Sorafenib: 8 cycles;
Capecitabine: 8 cycles;
Oxaliplatin: 8 cycles;
TACE (Cisplatin): 4X
301 TACE (Cisplatin): 4X;
Anti-VEGF: 9 cycles
302 Anti-VEGF: 4 cycles
403 Hepatectomy;
Anti-VEGF: 2 cycles
TACE (Cisplatin): 8X
405 Doxorubicin: 3 cycles;
Anti-VEGF: 14 cycles;
TACE (Cisplatin) : 8X
406 Hepatectomy only
TACE Transarterial chemo-embolization; Anti-VEGF Anti vascular
endothelial growth factor
Table 2 Demographics, baseline characteristic and prior treatment of
15 patients administrated with Peg-rhArg1
No. of
Patients
Percentage
(%)
Characteristics
Sex
Male 12 80
Female 3 20
Age (years)
Median 57
Range 33–74
Karnofsky Performance Scale
100 6 40
90 7 46.7
80 2 13.3
Hepatitis Serology
Hep Bs Ag positive 13 86.7
Child-Pugh Status
A 11 73.3
B 4 26.7
Alpha-fetal Protein (AFP)
<0400 5 33.3
>400 10 66.7
Disease stage at the time of study
entry
AJCC Staging
IIIA 4 26.7
IIIC 3 20
IV 8 53.3
BCLC Staging
C 15 100
Distant Metastases
Lung 6 40
Bone 1 6.7
Adrenal 2 13.3
Brain 1 6.7
Invasion of Major Vessels
Portal vein invasion 5 33.3
Prior Treatment
Surgical treatment
Liver resection 5 33.3
Laparotomy 1 6.7
Local ablative procedures
TACE 6 40
RFA 1 6.7
Systemic therapy 7 46.7
AJCC American Joint Committee on Cancer staging; BCLC Barcelona
Clinic Liver Cancer staging; Hep Bs Ag Hepatitis B surface anti-
gen; TACE Transarterial chemo-embolization; RFA Radiofrequency
ablation
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lower tolerated dose of peg-rhArg1 to achieve adequate
arginine depletion.
Treatment efficacy and survival analysis
Of the 15 patients recruited, 7 patients were terminated
before formal radiological assessments for efficacy due to
the following reasons: 2 died of liver failure from advanced
cirrhosis, 3 patients died of rapid progressive diseases, 1 had
prolonged elevation of bilirubin (DLT) and 1 withdrew
voluntarily from treatment. Overall, 4 (26.7%) patients
achieved SD and was observed at all 4 dose levels, one
from each cohort. Notably, marked tumor necrosis was
observed in two cases without actual change in tumor
dimensions on CT (Fig. 3). The median baseline alpha-
fetal protein (AFP) level was 954 μg/L (range, 4-267000).
Among all the 15 enrolled patients, six patients (40%)
showed a decline in AFP compared with baseline during
the study.
The median PFS and OS for the entire study population
of 15 patients were 2.8 months (95% CI: 0.2–3.0 months)
(Fig. 4) and 5.1 months (95% CI: 0.2–14.8 months) respec-
tively. The patients with Child-Pugh A cirrhosis had signif-
icantly better median OS than the Child-Pugh B cirrhotic
patients (8.5 versus 1.8 months, p<0.008). Two patients
receiving peg-rhArg1 at 1000 U/kg and 1600 U/kg remained
SD for >6 months.
Conclusion
This is the first human clinical study using peg-rhArg1 in
the treatment of advanced human malignancy. We have
demonstrated that arginine depletion in humans can be
achieved safely with peg-rhAgr1 in a dose-response manner.
There was no treatment-related death and all the AEs, except
for the one possible case of DLT in cohort 4, were mild
grade 1 and 2 non-hematologic toxicities, such as nausea
and abdominal discomfort, which resolved spontaneously
with symptomatic treatment. Thus, the primary objectives
of the study were met and the recommended weekly dose
for future development of Peg-rhAgr1 was chosen as
1600U/kg.
As in any drug trials involving patients with severely
compromised liver functions, there is always a problem in
attributing the exact cause of dysfunction, whether due to
the test drug or progression of underlying liver disease, i.e.
cirrhosis, hepatitis or malignancy, often all three. Overall,
only 2 of the 15 patients in the entire study had possible
severe drug-related liver dysfunction, one in cohort 1 and
the other in cohort 4. The first patient had grade 3 elevation
of ALT/AST after the first injection and was taken off the
study. Before he went into hepatic encephalopathy with liver
failure, a CT scan confirmed progression of the liver tumour,
from which he died after 2 months off treatment. The second
case had grade 3 followed by 4 hyperbilirubinemia after a
single injection of peg-rhArg1. Since the patient had no
overt clinical signs of disease progression, this hyperbili-
brubinemia was deemed as DLT. Although great care was
taken to recruit patients with adequate life-expectancy into
the study, the poor outcomes of these patients early on in
their treatment illustrate how unpredictable the clinical
course of heavily pre-treated HCC patients with advanced
disease can be. In particular, nearly half of the recruited
patients were heavily pre-treated with various prior system
therapies, which might account for the rapid deterioration of
the recruited patients in the study. As per protocol require-
ment, the additional 3 cases were recruited into cohort 4, and
it was reassuring that no further liver DLT was observed.
The study was terminated on completion of all the 6 cases in
cohort 4 since the MTD and OBD—the two important
objective parameters the authors aimed to establish—had
already been found.
In terms of toxicity profiles, peg-rhAgr1 does have an
advantage over both ADI and sorafenib. When compared with
ADI, peg-rhAgr1 releases urea as a side product, which is
much less toxic than the ammonia that is released by ADI
treatment. This is important since in patients with compro-
mised liver function, as in most HCC cases, the extra ammonia
may make the patients more susceptible to develop HE. In-
deed, the most common AEs attributed to ADI include tran-
sient and reversible HE. Other toxicities reported in ADI
included skin and injection site necrosis and electrolyte distur-
bance, which were not seen in our study. Being aMycoplasma
product, ADI is a xeonbiotic immunogenic substance, despite
pegylation. It has been reported that neutralizing antibodies to
ADI developed ~50 days after initiation of treatment [11]. Peg-
Table 4 Summary of possible treatment related Adverse Events (AEs)
Total No. of AEs
Grade 1
(%)
Grade 2
(%)
Grade 3
(%)
Grade 4
(%)
Abdomen Pain 1 (6.7)
Diarrhea 2 (13.3)
Nausea 1 (6.7)
Elevated ALT 1 (6.7)
Elevated AST 1 (6.7)
Elevated
Bilirubin
1 (6.7) 1 (6.7)
Elevated GGT 1 (6.7)
All AEs were scored according to the National Cancer institute (NCI)
Common Terminology Criteria, Version 3, June 10, 2003
ALT Alanine Transaminase; AST Asparate Transaminase; GGT
Gamma-glutamyl transferase
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rhAgr1, on the other hand, is a recombinant human hepatic
enzyme and in our preclinical and clinical studies (data not
shown); no evidence of immunogenicity has been found to
date. This has important therapeutic implication since the
neutralizing antibodies would render the drug ineffective as
an arginine-depleting agent. It was also reported in the ADI
studies that arginine levels would rise in the second month of
treatment, coinciding with the development of neutralizing
Fig. 2 a. Plasma Peg-rhArg1 level after single and multiple doses of Peg-rhArg1 in HCC patients b. Plasma arginine concentration after single and
multiple dosing of Peg-rhArg1 in HCC patients
Fig. 3 Computerized
Tomographic (CT) Scan of
HCC Patient: Serial CT scan
images of liver tumor before
treatment, 11 weeks after
treatment showing the increase
of necrosis with diameter of
25.6 mm, and 27 weeks after
treatment showing necrosis
with diameter of 71.8 mm,
respectively
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antibodies to ADI. On the other hand, neutralizing antibodies
to Peg-rhAgr1 have not been detected thus far in the present
study and it is reassuring that arginine levels remained at lower
levels throughout the entire study as long as treatment contin-
ued. More importantly, the AEs profile of peg-rhAgr1 also
compares favourably with that of sorafenib, which has large
numbers of grade III and IV toxicities in terms of hand-foot-
skin reaction, hypertension and rash. Again, none of these were
seen in this study.
Enzymatic depletion or deprivation therapy, whether with
peg-rhAgr1 or ADI, has now emerged as a new platform of
anti-cancer treatment in a number of human malignancies,
such as HCC and melanoma [18]. In vitro and in vivo
xenograft studies suggest that this mode of treatment is
efficacious also in prostatic and renal cell cancers, in which
ASS and arginosuccinate lyase (ASL) were highly repressed
or absent in an MD Anderson series [19]. Pegylated human
arginase has recently been shown in one US study to induce
remission in acute T cell leukemia [20]. The present study
serves to prove the concept that arginine depletion is really a
promising approach in treating advanced HCC patients.
Thus, further evaluation of peg-rhArg1 in future phase-II
trials of advanced HCC is warranted.
Peg-rhAgr1 might have demonstrated early activity in the
group of heavily pre-treated advanced HCC patients. Of the
8 cases completed 8 weeks of treatment and beyond, 4 had
durable SD lasting for 3 m+, 6 m+, 6 m+ and 3 m+, respec-
tively with drop in AFP level. One patient had minor shrink-
age of the target lung lesions that did not qualify as a partial
response by the RECIST 1.0 criteria. As experienced by other
clinical investigators in the field of HCC, assessing CT re-
sponse to treatment in HCC is notoriously difficult and tumour
response may result in tumour necrosis instead of shrinkage
(Fig. 2) [21]. Notably, at the time when this study was
conducted, RECIST 1.0 criteria was the standard for assessing
tumor response [22]. As yet, there is no consensus in the HCC
community about which new radiological criteria, such as
EASL [13] or modified RECIST [21] would be a better
method to assess response in HCC patients receiving targeted
therapy or biological therapy alone. Unfortunately, 7 enrolled
patients were not evaluable for treatment response and most of
these patients discontinued the therapy early mainly due to
either rapid disease progression or various complications from
underlying cirrhosis. This indeed reflects the challenges in
conducting clinical trials in this refractory patient population
with aggressive tumour biology and poor liver reserve.
In conclusion, peg-rhArg1 has a manageable safety pro-
file and is potentially a superior arginine depleting agent
than ADI in the treatment of human malignancies due to its
low toxicity profile and sustainable arginine depletion. The
optimal therapeutic dose of peg-rhArgI is 1600U/kg in
humans for future studies in advanced HCC patients.
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